Synthpop
Category: AI in Healthcare
An agentic AI platform designed to automate complex healthcare administrative workflows, such as referral management, medical order processing, and insurance verification. Synthpop was founded in 2023. The company is led by Elad Ferber. Based in Brooklyn, USA. Team size: 11-50. Total funding raised: $17.6M. Latest round: Series A (Feb 2026). Key investors include ["Peterson Ventures","Newfund Capital","Zelda Ventures","OVO Fund","defy.vc"].
- Founded
- 2023
- Headquarters
- Brooklyn, USA
- Team size
- 11-50
- Total funding
- $17.6M
Value proposition
Automates up to 80% of healthcare business processes to eliminate manual 'fax-and-phone' workflows, reducing administrative burnout and accelerating patient time-to-treatment.
Products and solutions
["Fax Wrangler (Automated document sorting and routing)","Field Extractor (Structured data extraction from unstructured medical records)","Order Validation (Real-time checking against clinical and payer guidelines)","AI Caller (Conversational voice agents for gathering insurance information)","Smart Scribe (Ambient AI for generating SOAP notes and visit summaries)","Intake Assistant (End-to-end processing of incoming multi-page medical orders)"]
Unique value
Utilizes 'Agentic AI'—autonomous agents capable of executing multi-step clinical tasks end-to-end (e.g., updating EHRs and making outbound calls) rather than just providing text summaries.
Target customer
Durable Medical Equipment (DME) providers, Independent Diagnostic Testing Facilities (IDTFs), specialized medical practices (Sleep Medicine, Wound Care, Genetic Testing), and large health systems.
Industries served
["Healthcare Administration","HealthTech","Medical Billing & RCM","Artificial Intelligence"]
Technology advantage
Built on a proprietary 'Composable Intelligence' framework; the technical team includes core contributors to Microsoft’s AutoGen framework (following the acquisition of the startup airt), enabling advanced multi-agent orchestration.
How they differentiate
Utilizes 'Agentic AI' to autonomously execute end-to-end clinical tasks—such as making outbound insurance calls and updating EHRs—rather than just providing data extraction or text summaries.
Main competitors
["Tennr","Notable Health","Regard"]
Key partnerships
["Bonafide (Strategic partnership for DME software integration)","Microsoft (Collaboration via AutoGen open-source contributions)","Peterson Ventures, Newfund Capital, and defy.vc (Key investment partners)"]
Notable customers
["Bonafide","Mount Sinai Health System (Clinical Lead connection)","Specialized Medical Practices (Sleep Medicine, Wound Care)"]
Major milestones
["Seed funding led by Peterson Ventures in Jan 2024","Strategic partnership with Bonafide for DME software integration","Acquisition of the 'airt' startup team to integrate core contributors of Microsoft’s AutoGen framework","Series A funding secured in Feb 2026 to scale healthcare AI operations"]
Growth metrics
Automating up to 80% of healthcare business processes; expanded technical team through the acquisition of the 'airt' startup team.
Market positioning
Specialized Healthcare AI provider focused on automating high-friction administrative 'paperwork' workflows for DME providers and specialized medical practices.
Geographic focus
North America
Patents and IP
CEO Elad Ferber holds multiple patents related to medical data processing and monitoring (e.g., US10893836B2); specific Synthpop-assigned patents are currently in the filing/non-public stage.
About Elad Ferber
Co-founder and CEO of Spry Health (acquired by Itamar Medical/ZOLL); VP of Remote Patient Monitoring at Itamar Medical; background in Aerospace Engineering and MBA from Stanford.
Official website: https://www.synthpop.ai